Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X by Rich Law, CBO of Haya Therapeutics! (formerly Exscientia/Recursion CBO), PhD adding:
“Tell that to the thousands of patients with chemo-refractory cancers who are alive today because of ADCs. No single drug (or drug class) will ‘solve cancer.’
Innovation = expanding the therapeutic arsenal and using it more precisely via biomarkers and clinical judgement.”
Quoting Rich Law’s post:
“ADCs are not innovation, other than the fact that the name is innovative marketing! (Antibody Conjugated Chemo – ACCs?).
Attaching an antibody to an old school toxic chemo warhead is not going to solve cancer really.”
Other articles featuring Paolo Tarantino on OncoDaily.